Patients
9.1 per 100,000 people
Suicide rate, Canada, 2023 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Canada Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$52.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $34.4 Mn | — | — |
| 2025 (base) | $37.8 Mn | +$3.5 Mn | — |
| 2026 (forecast) | $41.6 Mn | +$3.8 Mn | +10.1% |
| 2027 (forecast) | $45.8 Mn | +$4.2 Mn | +21.2% |
| 2028 (forecast) | $50.5 Mn | +$4.6 Mn | +33.5% |
| 2029 (forecast) | $55.6 Mn | +$5.1 Mn | +46.9% |
| 2030 (forecast) | $61.2 Mn | +$5.6 Mn | +61.8% |
| 2031 (forecast) | $67.4 Mn | +$6.2 Mn | +78.1% |
| 2032 (forecast) | $74.2 Mn | +$6.8 Mn | +96.1% |
| 2033 (forecast) | $81.7 Mn | +$7.5 Mn | +115.9% |
| 2034 (forecast) | $89.9 Mn | +$8.2 Mn | +137.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $37.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $89.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 10.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, application and end user (see all) |
| Key players | Myriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all) |
| Regulator in Canada | Health CanadaSource: Health Canada. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.
Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.
The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Health Canada licenses Class II, III and IV medical devices; Class I devices are sold by companies that hold an establishment licence.[1] Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services.[2] Suicide rate: 9.1 per 100,000 people in 2023, the latest WHO figure for Canada.[3]
[1] Health Canada. Checked 14 Nov 2026.
[2] Health Canada. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Canada.
What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.
9.1 per 100,000 people
Suicide rate, Canada, 2023 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
From our blog
Canada · 2 shared keywords
Canada · 1 shared keyword
Canada · 1 shared keyword
Canada
Canada
Canada
Pharmaceuticals · Canada
OTC & Nutraceuticals · Canada
Pharmaceuticals · Canada
Digital Health · Canada
Digital Health · Canada
Digital Health · Canada